Pay in 4 interest-free payments of $6.51 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The Food and Drug Administration (FDA) has approved two GLP-1 weight loss drugs for pediatric patients ages 12 to 17 with obesity: Saxenda and Wegovy
PMC 8717485
36 , 130143.e135 (2024)
These benefits are particularly evident in conditions like nonalcoholic steatohepatitis (NASH), where GLP-1RAs alleviate inflammation and boost insulin sensitivity, leading to improved hepatic glucose management and reduced steatosis (Zheng et al., 2024)
US$ 22.99
US$ 25.46
US$ 25.67
US$ 23.57
US$ 20.58
